Momelotinib (Omjjara®). HTA ID: 24002

Assessment Status Rapid Review Complete
HTA ID 24002
Drug Momelotinib
Brand Omjjara®
Indication Momelotinib (Omjjara®) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
Assessment Process
Rapid review commissioned 22/01/2024
Rapid review completed 22/02/2024
Rapid review outcome A full HTA is not recommended. The NCPE recommends that momelotinib not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.